Compare Biomaxima SA with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- The company is Net-Debt Free
2
High Debt company with Weak Long Term Fundamental Strength
3
The company has declared Negative results for the last 8 consecutive quarters
4
With ROE of 1.39%, it has a attractive valuation with a 1.12 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.91%
0%
-13.91%
6 Months
-15.56%
0%
-15.56%
1 Year
-13.23%
0%
-13.23%
2 Years
-21.57%
0%
-21.57%
3 Years
-56.27%
0%
-56.27%
4 Years
-39.25%
0%
-39.25%
5 Years
-62.26%
0%
-62.26%
Biomaxima SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.88%
EBIT Growth (5y)
-40.97%
EBIT to Interest (avg)
11.03
Debt to EBITDA (avg)
2.19
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
0.85
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
26.53%
ROE (avg)
24.44%
Valuation key factors
Factor
Value
P/E Ratio
53
Industry P/E
Price to Book Value
1.12
EV to EBIT
66.45
EV to EBITDA
16.34
EV to Capital Employed
1.10
EV to Sales
1.12
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
0.70%
ROE (Latest)
1.39%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
15.00
12.90
16.28%
Operating Profit (PBDIT) excl Other Income
0.40
0.30
33.33%
Interest
0.30
0.40
-25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.30
-0.60
50.00%
Operating Profit Margin (Excl OI)
-34.20%
-51.80%
1.76%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 16.28% vs -15.69% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 50.00% vs -200.00% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
52.90
46.80
13.03%
Operating Profit (PBDIT) excl Other Income
3.80
1.80
111.11%
Interest
1.00
0.60
66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.50
0.60
-16.67%
Operating Profit Margin (Excl OI)
8.10%
-13.60%
2.17%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.03% vs -67.48% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -16.67% vs -97.92% in Dec 2023
About Biomaxima SA 
Biomaxima SA
Pharmaceuticals & Biotechnology
BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
Company Coordinates 
Company Details
Ul. Vetterow 5 , LUBLIN None : 20-277
Registrar Details






